<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04705480</url>
  </required_header>
  <id_info>
    <org_study_id>20-718</org_study_id>
    <nct_id>NCT04705480</nct_id>
  </id_info>
  <brief_title>Pregabalin vs. Gabapentin on Reducing Opioid Usage</brief_title>
  <official_title>Pregabalin vs. Gabapentin on Reducing Opioid Usage in Trauma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CAMC Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CAMC Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, randomized, open-label, Phase 4 clinical trial investigating the&#xD;
      efficacy of multiple-dose administrations of Pregabalin or Gabapentin in combination with&#xD;
      traditional opioid pain medications to decrease the amount of opioid pain medication usage in&#xD;
      single-system orthopedic trauma patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 12, 2021</start_date>
  <completion_date type="Anticipated">April 12, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 12, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in opioid usage</measure>
    <time_frame>First 7 days post-enrollment or until discharge, if discharge &lt; 7 days post-enrollment</time_frame>
    <description>To determine if adding multiple doses of pregabalin or gabapentin upon admission will reduce opioid usage administered in oral Morphine Milligram Equivalents in trauma patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incentive spirometry values</measure>
    <time_frame>First 7 days post-enrollment or until discharge, if discharge &lt; 7 days post-enrollment</time_frame>
    <description>To compare the change in documented incentive spirometry values (liters) from morning physical assessment among patients in each of the study groups who have at least 1 rib fracture.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of intubation</measure>
    <time_frame>First 7 days post-enrollment or until discharge, if discharge &lt; 7 days post-enrollment</time_frame>
    <description>To compare the proportion of patients requiring intubation among the study groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain control</measure>
    <time_frame>First 7 days post-enrolment or until discharge, if discharge &lt; 7 days post-enrollment</time_frame>
    <description>To assess effectiveness of pain control in each arm based on the average Numeric Pain Rating Scale score per 24 hours. This scale is a 10 point numeric scale that ranges from 0 that represents &quot;no pain&quot; to 10 which indicates the &quot;worst pain imaginable.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>First 7 days post-enrollment or until discharge, if discharge &lt; 7 days post-enrollment</time_frame>
    <description>To evaluate the differences among the study arms with respect to hospital length of stay (days).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of unplanned ICU admission</measure>
    <time_frame>First 7 days post-enrollment or until discharge, if discharge &lt; 7 days post-enrollment</time_frame>
    <description>To evaluate the differences among the study arms with respect to proportion of unplanned ICU admission.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Analgesics</condition>
  <condition>Gabapentin</condition>
  <condition>Injuries</condition>
  <condition>Narcotics</condition>
  <condition>Pain</condition>
  <condition>Trauma</condition>
  <arm_group>
    <arm_group_label>Pregabalin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Gabapentin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Neither Pregabalin nor Gabapentin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin 50mg</intervention_name>
    <description>Patients will receive 50 mg every 8 hours without dose titration. Patients with CrCl &lt; 60mL/min will receive same dose given q12 hours. The q12 hour regimen may be increased to q8 hours if CrCl increases above 60mL/min during the 7 days study period or until discharge (if &lt; 7 days post-enrollment).</description>
    <arm_group_label>Pregabalin</arm_group_label>
    <other_name>Lyrica</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin 300mg</intervention_name>
    <description>Patients will receive 300 mg PO every 8 hours without dose titration. Patients with CrCl &lt; 60mL/min will receive same dose given q12 hours. The q12 hour regimen may be increased to q8 hours if CrCl increases above 60mL/min during the 7 days study period or until discharge (if &lt; 7 days post-enrollment).</description>
    <arm_group_label>Gabapentin</arm_group_label>
    <other_name>Neurontin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neither Pregabalin nor Gabapentin</intervention_name>
    <description>Patients will receive neither Pregabalin nor Gabapentin.</description>
    <arm_group_label>Neither Pregabalin nor Gabapentin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Nurse Practitioner service admissions&#xD;
&#xD;
          2. 18 to 65 year of age&#xD;
&#xD;
          3. Patients enrolled within 24 hours of admission&#xD;
&#xD;
          4. Anticipated duration of hospitalization &gt; 24 hours from time of consent&#xD;
&#xD;
          5. Active order(s) for opioids in place at the time of enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinician discretion based on patient care management&#xD;
&#xD;
          2. Intubated patients&#xD;
&#xD;
          3. Patients with epidural&#xD;
&#xD;
          4. Patients with pregabalin/gabapentin as home medications&#xD;
&#xD;
          5. Patients receiving pregabalin/gabapentin upon admission&#xD;
&#xD;
          6. Traumatic brain injury patients&#xD;
&#xD;
          7. CrCl&lt;30ml/min or on HD&#xD;
&#xD;
          8. Unable to take enteral medications&#xD;
&#xD;
          9. On Patient Controlled Analgesia (PCA)&#xD;
&#xD;
         10. Patients with complicated wound closure&#xD;
&#xD;
         11. History of epilepsy&#xD;
&#xD;
         12. Documented history of substance use disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>John A DeLuca, MD</last_name>
    <phone>3043887278</phone>
    <email>john.deluca@camc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Charleston Area Medical Center&quot;s Level 1 Trauma Center</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aous Jarrouj, MD, MBA, MHM</last_name>
      <phone>304-388-7808</phone>
      <email>aous.jarrouj@camc.org</email>
    </contact>
    <contact_backup>
      <last_name>Nancy Duvall, RN-BC, MS</last_name>
      <phone>3043889989</phone>
      <email>nancy.duvall@camc.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 8, 2021</study_first_submitted>
  <study_first_submitted_qc>January 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2021</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>CAMC Health System</investigator_affiliation>
    <investigator_full_name>John DeLuca</investigator_full_name>
    <investigator_title>Trauma Surgeon</investigator_title>
  </responsible_party>
  <keyword>Pregabalin , ,</keyword>
  <keyword>Gabapentin</keyword>
  <keyword>Opioid Pain Medication Use</keyword>
  <keyword>Trauma</keyword>
  <keyword>Opioid Usage Reduction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
    <mesh_term>Gabapentin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

